Oral Topoisomerase 1 Inhibitors in Adult Patients: Present and Future

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Investigational new drugs

• Publication date

  1999-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1023/A:1006394610219PMID 10759406
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intracellular Target of the Anticancer Drug Camptothecin Identification of Mammalian DNA Topoisomerase I as an Updated

  2006cited by this paper
• Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit

  2004cited by this paper
• Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan

  2004cited by this paper
• Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

  2004cited by this paper
• Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors

  2004cited by this paper
• Limited Sampling Models for Irinotecan Pharmacokinetics

  1999cited by this paper
• Oral topotecan: bioavailability and effect of food co-administration

  1999cited by this paper
• Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.

  1999cited by this paper
• Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.

  1999cited by this paper
• Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.

  1999cited by this paper
• Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.

  1999cited by this paper
• Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.

  1999cited by this paper
• Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study

  1999cited by this paper
• Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis.

  1999cited by this paper
• A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer.

  1999cited by this paper
• The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase.

  1999cited by this paper
• Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.

  1999cited by this paper
• Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.

  1999cited by this paper
• Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy.

  1999cited by this paper
• Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11.

  1998cited by this paper
• Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro

  1998cited by this paper
• Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.

  1998cited by this paper
• Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.

  1998cited by this paper
• Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.

  1998cited by this paper
• Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.

  1998cited by this paper
• Oral chemotherapy: rationale and future directions.

  1998cited by this paper
• Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer

  1998cited by this paper
• Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer.

  1998cited by this paper
• Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.

  1998cited by this paper
• Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071)

  1998cited by this paper
• Irinotecan (CPT-11) metabolism and disposition in cancer patients.

  1998cited by this paper
• Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.

  1998cited by this paper
• A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.

  1998cited by this paper
• Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.

  1998cited by this paper
• Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.

  1998cited by this paper
• Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.

  1998cited by this paper
• Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.

  1998cited by this paper
• In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems

  1998cited by this paper
• Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces.

  1998cited by this paper
• Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas.

  1998cited by this paper
• A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor

  1998cited by this paper
• Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.

  1998cited by this paper
• The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.

  1997cited by this paper
• Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice

  1997cited by this paper
• A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)

  1997cited by this paper
• An overview of the clinical pharmacology of topotecan.

  1997cited by this paper
• Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.

  1997cited by this paper
• Topoisomerase I inhibitors: review and update.

  1997cited by this paper
• Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma.

  1997cited by this paper
• A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer

  1997cited by this paper
• Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.

  1997cited by this paper
• Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection.

  1997cited by this paper
• Patient preferences for oral versus intravenous palliative chemotherapy.

  1997cited by this paper
• Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.

  1997cited by this paper
• Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients.

  1997cited by this paper
• A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer.

  1997cited by this paper
• Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.

  1997cited by this paper
• Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

  1997cited by this paper
• Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.

  1996cited by this paper
• Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.

  1996cited by this paper
• Phase I Clinical and Pharmacological Studies of 20‐(S)‐Camptothecin and 20‐(S)‐9‐Nitrocamptothecin as Anticancer Agents

  1996cited by this paper
• Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients.

  1996cited by this paper
• Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.

  1996cited by this paper
• Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.

  1996cited by this paper
• Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase.

  1996cited by this paper
• Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.

  1996cited by this paper
• Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin.

  1996cited by this paper
• Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

  1996cited by this paper
• Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.

  1996cited by this paper
• Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.

  1996cited by this paper
• Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.

  1996cited by this paper
• Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.

  1996cited by this paper
• Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure

  1996cited by this paper
• Pharmacodynamics/pharmacokinetics of intragastric camptothecin analogs in a human-cancer xenograft model

  1995cited by this paper
• Metabolism of irinotecan to SN-38 in a tissue-isolated tumor model.

  1995cited by this paper
• The mechanisms of DNA topoisomerases.

  1995cited by this paper
• Antitumor effect of liposome‐incorporated camptothecin in human malignant xenografts

  1995cited by this paper
• A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.

  1995cited by this paper
• Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

  1995cited by this paper
• Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.

  1994cited by this paper
• Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice.

  1994cited by this paper
• Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.

  1994cited by this paper
• Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group.

  1994cited by this paper
• Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.

  1994cited by this paper
• Therapeutic efficacy of camptothecin derivatives against human malignant melanoma xenografts

  1994cited by this paper
• Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.

  1994cited by this paper
• Studies of time/dose intensity in treatment of human cancer xenografts with camptothecin analogues

  1994cited by this paper
• Mechanisms of resistance to topoisomerase inhibitors.

  1994cited by this paper
• Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.

  1994cited by this paper
• Conversion of 9‐nitro‐camptothecin to 9‐amino‐camptothecin by human blood cells in vitro

  1994cited by this paper
• Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor.

  1993cited by this paper
• Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor.

  1993cited by this paper
• Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.

  1993cited by this paper
• Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non‐tumorigenic and tumorigenic cells in vitro

  1993cited by this paper
• Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice.

  1993cited by this paper
• CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer.

  1992cited by this paper
• Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

  1992cited by this paper
• Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.

  1992cited by this paper
• Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins.

  1992cited by this paper
• Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin.

  1991cited by this paper

• In Vivo and In Vitro Pharmacokinetic Studies of a Dual Topoisomerase I/II Inhibitor.

  2025cites this paper
• Mechanisms underlying dose-limiting toxicities of conventional chemotherapeutic agents

  2024cites this paper
• Characterising changes in adhesion and enzyme activity related to drug resistance in colon cancer cells

  2018cites this paper
• Chemistry and Biology of Camptothecin and its Derivatives 22

  2013cites this paper
• Oral delivery of anticancer drugs II: the prodrug strategy.

  2013cites this paper
• Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization.

  2012cites this paper
• In Situ intestinal perfusion of irinotecan: application to P-gp mediated drug interaction and introduction of an improved HPLC assay.

  2011cites this paper
• Antiproliferative cardenolides from Pentopetia androsaemifolia Decne. from the Madagascar rain forest.

  2010cites this paper
• Diflomotecan, a promising homocamptothecin for cancer therapy

  2009cites this paper
• UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?

  2009cites this paper
• Photoaffinity Isolation and Identification of Proteins in Cancer Cell Extracts that Bind to Platinum‐Modified DNA

  2009cites this paper
• A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?

  2009cites this paper
• Oral Anticancer Drugs in the Elderly

  2007cites this paper
• Towards new camptothecins. Part 2: Synthesis of the ABCD ring scaffold substituted by a carboxyl group in the 5-position

  2005cites this paper
• Development and characterization of a novel liposome-based formulation of SN-38.

  2004cites this paper
• Unexpected interactions between nicotinamide and CPT-11 in a rhabdomyosarcoma tumor model.

  2003cites this paper
• Clinical studies of camptothecin and derivatives.

  2003cites this paper
• Studies on pyrrolidinones. Synthesis of new α‐pyridones derivatives

  2003cites this paper
• Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11

  2003cites this paper
• Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.

  2003cites this paper
• Urinary and fecal excretion of topotecan in patients with malignant solid tumours

  2002cites this paper
• Chemoradiation with novel agents for rectal cancer.

  2002cites this paper
• The use of oral cytotoxic and cytostatic drugs in cancer treatment.

  2002cites this paper
• Current status and perspectives in the development of camptothecins.

  2002cites this paper
• Oral Chemotherapy for the Older Patient with Cancer

  2002cites this paper
• Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.

  2001cites this paper
• Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

  2001cites this paper
• Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?

  2001cites this paper
• Modulation of camptothecin analogs in the treatment of cancer: a review

  2001cites this paper
• Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?

  2001cites this paper
• The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison

  2001cites this paper
• Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography

  2000cites this paper